JP2005526695A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005526695A5 JP2005526695A5 JP2003526388A JP2003526388A JP2005526695A5 JP 2005526695 A5 JP2005526695 A5 JP 2005526695A5 JP 2003526388 A JP2003526388 A JP 2003526388A JP 2003526388 A JP2003526388 A JP 2003526388A JP 2005526695 A5 JP2005526695 A5 JP 2005526695A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- stereoisomers
- stereoisomer
- substantially free
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 15
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31867201P | 2001-09-13 | 2001-09-13 | |
| US32519201P | 2001-09-28 | 2001-09-28 | |
| PCT/US2002/029014 WO2003022259A1 (en) | 2001-09-13 | 2002-09-12 | Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005526695A JP2005526695A (ja) | 2005-09-08 |
| JP2005526695A5 true JP2005526695A5 (https=) | 2009-01-22 |
Family
ID=26981614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003526388A Pending JP2005526695A (ja) | 2001-09-13 | 2002-09-12 | シブトラミンおよびそれの代謝物の２−ヒドロキシ誘導体の製造方法および使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20030087963A1 (https=) |
| EP (1) | EP1434575A4 (https=) |
| JP (1) | JP2005526695A (https=) |
| AU (1) | AU2002326883B2 (https=) |
| CA (1) | CA2460348A1 (https=) |
| WO (1) | WO2003022259A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
| US20070032554A1 (en) * | 2003-08-27 | 2007-02-08 | Elililly And Company A Corporation | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors |
| WO2005072715A1 (en) * | 2004-01-29 | 2005-08-11 | Sepracor Inc. | Use of (s)-didesmethylsibutraminefor treating, preventing and managing a sleep disorder |
| WO2005079851A2 (en) | 2004-02-18 | 2005-09-01 | Sepracor, Inc. | Dopamine-agonist combination therapy with sedatives for improving sleep quality |
| US8604244B2 (en) | 2010-07-02 | 2013-12-10 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives |
| WO2008034142A2 (en) * | 2006-09-15 | 2008-03-20 | Reviva Pharmaceuticals, Inc. | Synthesis, methods of using, and compositions of cycloalkylmethylamines |
| ES2763873T3 (es) | 2007-06-21 | 2020-06-01 | Veroscience Llc | Método de tratamiento de trastornos metabólicos y depresión con agonistas del receptor de dopamina |
| US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3155669A (en) | 1962-06-22 | 1964-11-03 | Res Lab Dr C Janssen N V | 2, 4, 8-triaza-spiro (4, 5) dec-2-enes |
| US3155670A (en) | 1962-06-22 | 1964-11-03 | Res Lab Dr C Janssen N V | 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes |
| US3471515A (en) | 1965-02-01 | 1969-10-07 | Sandoz Ag | (2-hydroxy-3-substituted aminopropoxy)indoles |
| US3466325A (en) | 1965-04-30 | 1969-09-09 | Haessle Ab | 1-(ortho-alkenyl phenoxy) - 2-hydroxy-3-isopropylaminopropanes and the salts thereof |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| GB1308191A (en) | 1970-04-06 | 1973-02-21 | Science Union & Cie | Thiochroman derivatives and a process for preparing them |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| GB8501192D0 (en) * | 1985-01-17 | 1985-02-20 | Boots Co Plc | Therapeutic agents |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| GB8909209D0 (en) | 1989-04-22 | 1989-06-07 | Wyeth John & Brother Ltd | Piperazine derivatives |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| CA2134038C (en) | 1994-06-16 | 1997-06-03 | David Taiwai Wong | Potentiation of drug response |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| EP0934941A1 (en) | 1996-08-09 | 1999-08-11 | Eisai Co., Ltd. | Benzopiperidine derivatives |
| US6127363A (en) | 1997-10-28 | 2000-10-03 | Vivus, Inc. | Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction |
-
2002
- 2002-09-11 US US10/238,630 patent/US20030087963A1/en not_active Abandoned
- 2002-09-12 WO PCT/US2002/029014 patent/WO2003022259A1/en not_active Ceased
- 2002-09-12 JP JP2003526388A patent/JP2005526695A/ja active Pending
- 2002-09-12 AU AU2002326883A patent/AU2002326883B2/en not_active Ceased
- 2002-09-12 CA CA002460348A patent/CA2460348A1/en not_active Abandoned
- 2002-09-12 EP EP02761634A patent/EP1434575A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004048345A3 (en) | 2,5-diketopiperazines for the treatment of obesity | |
| CA2429844A1 (en) | Mch antagonists and their use in the treatment of obesity | |
| CA2521509A1 (en) | Fast dissolving orally consumable films containing pharmaceutically active agents | |
| SI1465608T1 (sl) | Sestavki s podaljšanim sproščanjem, ki obsegajo kot aktivno spojino venlafaksin hidroklorid | |
| RU2002125821A (ru) | Твердая дозированная форма симетикона для перорального применения | |
| BRPI0415449A (pt) | combinações de compostos ativos fungicidas sinergìsticos | |
| WO2002087508A3 (en) | Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use | |
| SE0201544D0 (sv) | Novel compounds and thier use | |
| RU2008142261A (ru) | Фармацевтическая композиция с модифицированным высвобождением и ее применение | |
| JP2005526695A5 (https=) | ||
| MX2009003713A (es) | Inhibidor de progresion de enfermedad de alzheimer que contiene un compuesto heterociclico con estructura especifica. | |
| AR052853A1 (es) | Composiciones orales que contienen compuestos antibacterianos de bifenol | |
| JP2006506499A5 (https=) | ||
| JP2005509503A5 (https=) | ||
| WO2004014290A3 (en) | R-bambuterol, its preparation and therapeutic uses | |
| CA2194175A1 (en) | Two- and three-component fungicidal mixtures | |
| WO2003018515A3 (en) | Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders | |
| JP2005528357A5 (https=) | ||
| WO2005000243A3 (en) | The polymorphic form a of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butryric acid | |
| NO20051282L (no) | Antitumorale analoger av lamellariner. | |
| CA2042673A1 (en) | Acetyl-tri- and tetramethyl-octahydronaphthalenes and fragrance compositions containing the same | |
| MXPA05008711A (es) | Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico. | |
| GB0504103D0 (en) | Novel method | |
| WO2004045283A3 (de) | Fungizide mischungen zur bekämpfung von reispathogenen | |
| WO2025024329A3 (en) | Compounds, compositions, and methods |